Upload
Featured Recent Articles Topics Login Upload

Search Results for 'treatment pfs'

treatment pfs published presentations and documents on DocSlides.

BELLE-3: A Phase III Study of
BELLE-3: A Phase III Study of
by faustina-dinatale
Buparlisib. and . Fulvestrant. in Postmenopausa...
End-points utilized in breast cancer
End-points utilized in breast cancer
by evelyn
clinical . trials - Discussion. Novartis Oncology...
Blinded Sample Size Re-estimation in a Phase III Study Inve
Blinded Sample Size Re-estimation in a Phase III Study Inve
by luanne-stotts
David Morgan (King’s College, London / Consulta...
Btk inhibition in Mantle cell Lymphoma & CLL
Btk inhibition in Mantle cell Lymphoma & CLL
by test
Simon Rule. Professor of Clinical . Haematology. ...
Managing Advanced Renal Cell
Managing Advanced Renal Cell
by debby-jeon
Carcinoma: Balancing . Efficacy with Quality of L...
End-points utilized in
End-points utilized in
by marina-yarberry
End-points utilized in breast cancer clinical ...
Game Plan Trends in ovarian cancer
Game Plan Trends in ovarian cancer
by alexa-scheidler
Diagnostic work-up. Treatment. The most commonly ...
2022 Spring Oncology Conference
2022 Spring Oncology Conference
by byrne
Evolving Treatment Strategies. for CLL/SLL and MCL...
ESMO 2021 (Virtual) Congress Report
ESMO 2021 (Virtual) Congress Report
by SnuggleBug
Lung and gastrointestinal cancers. Slide numbers. ...
Considerations for Optimizing Transplant in Multiple Myeloma Patient Management
Considerations for Optimizing Transplant in Multiple Myeloma Patient Management
by TravelingSoulmate
PARAMESWARAN HARI MD. MEDICAL COLLEGE OF WISCONSIN...
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
by naomi
David Morgan (King’s College, London / Consultan...
Summary 2011 Founded 2010
Summary 2011 Founded 2010
by eliza
in Houston. Vision: To be the leader in the develo...
Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m
Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m
by felicity
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor...
Treatment escalation in patients with early stage Hodgkin lymphoma and a positive PET scan after in
Treatment escalation in patients with early stage Hodgkin lymphoma and a positive PET scan after in
by fanny
. A subsidiary analysis of the UK NCRI RAPID study...
Chee Lee,
Chee Lee,
by olivia-moreira
MBBS (Hons), . MMedSci. (. Clin. . Epid. ), . M...
17th Annual International Congress
17th Annual International Congress
by conchita-marotz
on . Hematologic Malignancies. ®. : . Focus . on...
Multiple Myeloma – Is It Now Curable?
Multiple Myeloma – Is It Now Curable?
by celsa-spraggs
Andrzej . J. . Jakubowiak, MD, PhD. Director, Mye...
Second line
Second line
by alida-meadow
treatments. in WT . pts. : . which. . opportuni...
Please note, these are the actual video-recorded proceeding
Please note, these are the actual video-recorded proceeding
by luanne-stotts
Moderator. Neil Love, MD. Mollie Moran, MSN, CNP,...
Common Knee Injuries Meniscus Tears
Common Knee Injuries Meniscus Tears
by celsa-spraggs
Knee twisted suddenly. One or both menisci become...
CDK4-6 INHIBITORS IN Breast Cancer: Optimal Treatment Sequencing
CDK4-6 INHIBITORS IN Breast Cancer: Optimal Treatment Sequencing
by leah
Mansoor A Khan, BS, MS, BCOP. Oncology/Hematology/...
Efficacy of sorafenib in patients with
Efficacy of sorafenib in patients with
by caitlin
desmoid. -type . fibromatosis. Rodrigo Munhoz. 1. ...
R eal-world evidence Value, methodological strengths and weaknesses
R eal-world evidence Value, methodological strengths and weaknesses
by Ruggedman
What is RWE?. RWE, real-world evidence. .. 1. Food...
1171MO – PACIFIC-R Real-World Study:
1171MO – PACIFIC-R Real-World Study:
by riley
Treatment Duration and Interim Analysis of Progres...
Efficacy of
Efficacy of
by myesha-ticknor
sorafenib. in patients with . desmoid. -type . f...
Thierry
Thierry
by cheryl-pisano
Le Chevalier, . MD. The Role of Translational Res...
Update on transplant-ineligible patients:
Update on transplant-ineligible patients:
by trish-goza
Which . regimens are best?. Suzanne Lentzsch MD, ...
Treatment of
Treatment of
by natalia-silvester
Biliary. Cancers. Abby B. Siegel, MD, MS . Colum...
James Yang,
James Yang,
by pasty-toler
MD. The Evolving Treatment Landscape in NSCLC: Co...
Immunotherapy for
Immunotherapy for
by sherrill-nordquist
High-Risk and Metastatic Melanoma. Timothy M. Kuz...
Emanuele Zucca, MD Oncology Institute of Southern Switzerland (IOSI)
Emanuele Zucca, MD Oncology Institute of Southern Switzerland (IOSI)
by ellena-manuel
Swiss Group for Clinical Cancer Research (SAKK). ...
Indolent Non-Hodgkin L
Indolent Non-Hodgkin L
by danika-pritchard
ymphoma. Sobia Ozair. March 8, 2017. MD Anderson ...
Ovarian Cancer Incidence/Mortality
Ovarian Cancer Incidence/Mortality
by kittie-lecroy
Improvement in 5 Year Survival:. Race. 1975. 1989...
Please note, these are the actual video-recorded
Please note, these are the actual video-recorded
by chaptoe
proceedings from the live CME event and may includ...
Please note, these are the actual video-recorded
Please note, these are the actual video-recorded
by blindnessinfluenced
proceedings from the live CME event and may includ...
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
by maniakti
Richard S. Finn, MD. Professor of Clinical Medicin...
by billiontins
2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...
Colorectal Cancer in Older
Colorectal Cancer in Older
by stingraycartier
Patients. Key Issues. Etienne GC . Brain. , MD . P...
First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib P
First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib P
by mia
Ibr+Ven. ) Versus Chlorambucil Plus Obinutuzumab (...
Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat
Impact of Imatinib interruption & duration of prior Hydroxyurea on treatment outcome in CML pat
by hadly
Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof C...